Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.

OBJECTIVE The purpose of this study was to identify genes that are highly differentially expressed in metastatic serous papillary ovarian tumors (MET) when compared with primary ovarian serous carcinomas (OSPC). STUDY DESIGN An oligonucleotide microarray with probe sets complementary to >14,500 human genes was used to determine whether patterns of gene expression may differentiate OSPC from MET in 31 snap-frozen serous papillary ovarian carcinomas (ie, 14 primary OSPC and 17 omental metastasis [MET]). RESULTS Hierarchic cluster analysis of gene expression in OSPC and MET identified 156 genes that exhibited > 2-fold differences (P < .05) and that distinguished OSPC from MET. A number of invasion and metastasis predictive genes (including plasminogen activator; matrix metalloproteinase; matrix structural constituent genes encoding products with collagen, heparin, and hyaluronic acid binding activity; genes encoding receptors for insulin-like growth factors; vascular endothelial growth factor; endothelin type A; fibroblast growth factor; thrombospondin 1 and 2; type A and B integrins, and chemokines [stromal cell-derived factor 1 (CXCL12)]) were found among the 120 genes that were highly differentially overexpressed in MET, when compared with OSPC. Down-regulated genes in MET compared with OSPC included hepsin and testisin. Overexpression of CXCL12, matrix metalloproteinase, plasminogen activator, type A and B integrins, and hepsin genes was validated by quantitative real-time polymerase chain reaction in all samples. Finally, overexpression of CXCL12 in MET, when compared with OSPC, was validated at the protein level by immunohistochemistry. CONCLUSION Gene expression profiling may differentiate metastatic ovarian cancer from primary OSPC. The identification of metastasis-associated genes may provide a foundation for the development of new type-specific diagnostic strategies and treatment for metastatic ovarian cancer.

[1]  S. Calza,et al.  Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. , 2006, Gynecologic oncology.

[2]  Edward J. Fuchs,et al.  Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers , 2000, Antimicrobial Agents and Chemotherapy.

[3]  Nancy Wang.  Cytogenetics and molecular genetics of ovarian cancer. , 2002, American journal of medical genetics.

[4]  Lieve Moons,et al.  CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. , 2005, Cancer research.

[5]  F. Balkwill,et al.  Epithelial cancer cell migration: a role for chemokine receptors? , 2001, Cancer research.

[6]  N. Bertin,et al.  Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. , 1997, Cancer research.

[7]  Annuska M Glas,et al.  Gene expression profiles of primary breast tumors maintained in distant metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  O. Volpert,et al.  A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  N. Harbeck,et al.  Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function , 1998, FEBS letters.

[10]  G. Esposito,et al.  Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma , 2005, International journal of cancer.

[11]  A. Hongo,et al.  Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor. , 2001, Anticancer research.

[12]  S. Rabbani,et al.  Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. , 1998, International journal of oncology.

[13]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[14]  A. Krüger,et al.  High‐affinity urokinase‐derived cyclic peptides inhibiting urokinase/urokinase receptor‐interaction: effects on tumor growth and spread , 2002, FEBS letters.

[15]  P. Chambon,et al.  Stromelysin-3 gene expression in human cancer: an overview. , 1994, Invasion & metastasis.

[16]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[17]  Y. Hirashima,et al.  Suppression of Urokinase Expression and Invasiveness by Urinary Trypsin Inhibitor Is Mediated through Inhibition of Protein Kinase C- and MEK/ERK/c-Jun-dependent Signaling Pathways* , 2001, The Journal of Biological Chemistry.

[18]  T. Curiel,et al.  Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells , 2001, Nature Medicine.

[19]  H. Höfler,et al.  Stromelysin-3 expression in invasive ovarian carcinomas and tumours of low malignant potential , 2000, Virchows Archiv.

[20]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[21]  Norbert Gretz,et al.  Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. , 2005, Anticancer research.

[22]  Anne-Marie Mes-Masson,et al.  Signature of a silent killer: expression profiling in epithelial ovarian cancer , 2004, Expert review of molecular diagnostics.

[23]  R. Kimmig,et al.  Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.